ClinicalTrials.gg
RecruitingNCT06160635HDV750Updated Oct 1, 2026

D-SOLVE Cohorts (Cohort A and B)

An observational study in HDV, HDV Infection and Chronic Liver Disease, sponsored by Hannover Medical School. Recruiting at 4 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Hannover Medical School · Observational

How we know

From the registry’s dates

  • Started Feb 2023; still recruiting 3 years 9 months later.
Updated Oct 1, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
750
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Hepatitis D with a site in Germany — 3 open to participants now, 9 under way, 4 of them phase 3. Hepatitis D · Germany.

Started
2023
the only one that year
Observational
4 of 13
2 open now
Registered
8th of 13
by date
Lead sponsor
2 of 13
Hannover Medical School

Among the 13 studies in Hepatitis D with a site in Germany, this one is the only one that started in 2023, is one of 4 observational ones, and was the 8th registered.

Hepatitis D

63 studies on the registry are indexed under Hepatitis D; 21 are open to participants now.

Browse Hepatitis D studies →

Open to participants now

3 of the 13 studies in Hepatitis D with a site in Germany are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 14 Hepatitis D studies recruiting now, 9 (64%) set no upper age limit and 1 (7%) stops at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Hepatitis D with a site in Germany, or all of them as a file.
02

Study summary

Hepatitis D is by far the most severe form of chronic viral hepatitis, frequently leading to liver failure, hepatocellular carcinoma and death. Hepatitis D is caused by coinfection Hepatitis D is caused by co-infection with hepatitis B virus (HBV) and hepatitis D virus (HDV).

This multicenter cohort should enable a comprehensive and unbiased biomarker screening of well-defined HDV-infected patients, followed by mechanistic studies to determine the functional role of distinct molecules. Patient surveillance strategies and antiviral treatment approaches could be personalized which should reduce clinical and social disease burden, improve quality of life and save direct and indirect costs caused by HDV infection.

Read the detailed description

The D-SOLVE consortium ("Understanding the individual host response against Hepatitis D Virus to develop a personalized approach for the management of hepatitis D"), aims for an unbiased screening of a large multicenter cohort of well-defined HDV-infected patients to better understand individual factors determining the outcome of infection and to identify subjects benefitting from currently available treatments.

The D-SOLVE cohorts will be collected retrospectively as well as prospectively with clinical and virological data and biomaterial for the biomarker analysis. The aim of the cohorts is as following:

Cohort A: To define the demographic, clinical, virological, and immunological features of a large cross-sectional cohort of 750 untreated and treated HDV patients at 4 EU centers. To compare these features among patients with different origin, gender, disease severity and treatment. To collect biological material to generate translational studies, aimed to better understand pathogenesis, natural history and treatment response.

Cohort B: To identify histological and immunological features that are associated with fibrosis progression and clinical complications in patients with chronic HDV infection.

The D-SOLVE consortium has received funding from the Horizon 2020 EU Horizon Call "Personalised medicine and infectious diseases: understanding the individual host response to viruses (e.g. SARS-CoV-2)" of the European Union (grant agreement No 101057917). The consortium is coordinated by Hannover Medical School (MHH) and the Centre for Individualised Infection Medicine (CiiM). Other partners are:

  • Helmholtz-Zentrum für Infektionsforschung (HZI), Germany
  • Institut national de la santé et de la recherche médicale (INSERM)
  • Karolinska Institutet (KI), Sweden
  • Karolinska University Hospital / Region Stockholm (KUH), Sweden
  • Policlinico of Milan (PFM), Italy
  • National Institute for Infectious Diseases "Prof Dr Matei Balș" (INBIMB), Romania
  • Helmholtz-Zentrum für Informationssicherheit (CISPA), Germany

The Cohorts and the biomarker screening are part of the EU-funded D-SOLVE Consortium.

03

Conditions studied

  • HDV
  • HDV Infection
  • Chronic Liver Disease

Browse trials for

Keywords

  • HDV
  • Hepatitis Delta
  • chronic liver disease
  • patient cohort
  • biomarker
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All adult patients chronically infected with the hepatitis D virus (anti-HDV positive) can be included. For cohort B historical liver biopsies need to be available.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Anti-HDV positive
  • ≥18 years old
  • Sex: m/f/d
  • for prospective procedures

Exclusion criteria

Exclusion Criteria:

  • Anti-HDV negative
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
750 participants (estimated)
Target follow-up
3 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Cohort A

    Cohort A: Patients chronically infected with HDV. Patients with and without cirrhosis and with and without viremia will be included.

  • Cohort B

    Cohort B: Patients chronically infected with HDV and with available historical liver biopsies (5-20 years old biopsies) and clinical follow-up data or current patients willing to receive a core biopsy or fine-needle liver-cell aspirate (FNA). Patients with and without cirrhosis and with and without viremia will be included.

06

What researchers measure

Primary outcomes

  1. Biosample Screening

    Identification of biomarkers that are associated with disease control, progression and treatment response by a multiomics approach that includes the investigation of: - the genome by the Illumina Infinium Global Screening array - the transcriptome by RNA-sequencing and single-cell RNA-sequencing (subset of samples) - the proteome by the Olink technology (high throughput proximity extension assay) - the metabolome by HPLC 1H-NMR (\~2k metabolite features) - the methylome (Illumina 850k array) - immune phenotypes by high dimensional spectral flow cytometry - Spatial transcriptomics and multiplex imaging of HDV-patient liver biopsies

    Time frame: 3 years

Secondary outcomes

  1. Definition of the demographic, clinical and virological features of the cohort.

    Identification of immunological determinants of liver disease progression, viral control and treatment response by - scRNA/ATAC sequencing of Ag-specific T cells, NK cells and MAIT cells (PBMC) - spatial multiomics with feature barcoding technology of liver core biopsies - Validation of findings by 29-color flow cytometry, hepatoma HDV infection system and respective mouse models

    Time frame: 3 years

  2. Identification of virological and immunological features and characteristics that relate to disease severity and treatment response.

    Establishment of a computational model to predict immune responses and disease phenotype

    Time frame: 3 years

07

Study locations

3 of 4 sites recruiting
  • Hannover Medical School, Department of Gastroenterology, Hepatology, Infectious Disease and Endocrinology
    Hanover, 30625, Germany
    Recruiting
    • Heiner Wedemeyer · Contact
  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (University of Milan)
    Milan, Italy
    Not yet recruiting
    • Pietro Lampertico · Contact
  • Institutul de Boli Infectioase "Prof. Dr. Matei Bals"
    Bucharest, 021105, Romania
    Recruiting
    • Florin Alexandru Caruntu, Dr. · Contact
  • Karolinska University Hospital and Karolinska Institutet
    Stockholm, Sweden
    Recruiting
    • Soo Aleman · Contact
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Feb 2023 (actual). Primary completion is estimated for Sep 2027, 55 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 1, 2026: primary completion Sep 2026 → Sep 2027 and completion Sep 2026 → Sep 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2023
First posted
Dec 7, 2023
StartActual
Feb 22, 2023
Primary completionEst.
Sep 30, 2027was Sep 2026
CompletionEst.
Sep 30, 2027was Sep 2026
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Hannover Medical School, Department of Gastroenterology, Hepatology, Infectious Disease and Endocrinology · Hanover, Germany
Show 1 removed
  • Hannover Medical School, Department of Gastroenterology, Hepatology, Infectious Disease and Endocrinology · Hannover, Germany
Oct 1, 2026
Primary completion
Sep 30, 2026→Sep 30, 2027
Oct 1, 2026
Study completion
Sep 30, 2026→Sep 30, 2027
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    1 site added, 1 site removed
    Show site
    • Hannover Medical School, Department of Gastroenterology, Hepatology, Infectious Disease and Endocrinology · Hanover, Germany
    Show 1 removed
    • Hannover Medical School, Department of Gastroenterology, Hepatology, Infectious Disease and Endocrinology · Hannover, Germany
    Primary completion Sep 30, 2026→Sep 30, 2027
    Study completion Sep 30, 2026→Sep 30, 2027
    + 3 other changes: identifiers, verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06160635
Collaborators
Karolinska University Hospital, Karolinska Institutet, Helmholtz Centre for Infection Research, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, National Institute of Infectious Diseases Matei Bals
Responsible party
Sponsor
First posted
Dec 7, 2023
Start date
Feb 22, 2023
Primary completion
Sep 30, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Oct 1, 2026

Study contacts

Petra Dörge
Contact
doerge.petra@mh-hannover.de
+495115326057
Julia Kahlhöfer
Contact
kahlhoefer.julia@mh-hannover.de
Markus Cornberg
principal investigator · Hannover Medical School

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion